EE200300505A - Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks - Google Patents

Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks

Info

Publication number
EE200300505A
EE200300505A EEP200300505A EEP200300505A EE200300505A EE 200300505 A EE200300505 A EE 200300505A EE P200300505 A EEP200300505 A EE P200300505A EE P200300505 A EEP200300505 A EE P200300505A EE 200300505 A EE200300505 A EE 200300505A
Authority
EE
Estonia
Prior art keywords
infertility
medicament
manufacture
treatment
aromatase inhibitor
Prior art date
Application number
EEP200300505A
Other languages
English (en)
Estonian (et)
Inventor
F. Casper Robert
F. M. Mitwally Mohamed
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of EE200300505A publication Critical patent/EE200300505A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300505A 2001-04-17 2002-04-17 Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks EE200300505A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28428201P 2001-04-17 2001-04-17
PCT/CA2002/000527 WO2002083241A1 (en) 2001-04-17 2002-04-17 Single dose aromatase inhibitor for treating infertility

Publications (1)

Publication Number Publication Date
EE200300505A true EE200300505A (et) 2004-02-16

Family

ID=23089583

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300505A EE200300505A (et) 2001-04-17 2002-04-17 Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks

Country Status (32)

Country Link
US (1) US8008333B2 (enExample)
EP (1) EP1383578B1 (enExample)
JP (1) JP2004529924A (enExample)
KR (1) KR20040025916A (enExample)
CN (1) CN1551789A (enExample)
AR (1) AR034036A1 (enExample)
AT (1) ATE409066T1 (enExample)
AU (1) AU2002249043B2 (enExample)
BG (1) BG108323A (enExample)
BR (1) BR0208920A (enExample)
CA (1) CA2444980C (enExample)
CY (1) CY1108648T1 (enExample)
CZ (1) CZ20033107A3 (enExample)
DE (1) DE60229047D1 (enExample)
DK (1) DK1383578T3 (enExample)
EA (1) EA011310B1 (enExample)
EE (1) EE200300505A (enExample)
ES (1) ES2311599T3 (enExample)
HR (1) HRP20030839A2 (enExample)
HU (1) HUP0304003A2 (enExample)
IL (1) IL158396A0 (enExample)
MX (1) MXPA03009447A (enExample)
NO (1) NO20034246L (enExample)
NZ (1) NZ552873A (enExample)
PL (1) PL366744A1 (enExample)
PT (1) PT1383578E (enExample)
SI (1) SI1383578T1 (enExample)
SK (1) SK14242003A3 (enExample)
UA (1) UA82648C2 (enExample)
WO (1) WO2002083241A1 (enExample)
YU (1) YU81203A (enExample)
ZA (1) ZA200307516B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247404A1 (en) * 2002-07-02 2004-01-23 Pharmacia & Upjohn Company Llc Infertility treatment with exemestane
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2007000056A1 (en) * 2005-06-28 2007-01-04 Casper Robert F Aromatase inhibitors for emergency contraception
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
AU2011256088B2 (en) * 2010-05-20 2015-03-26 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
US10004723B2 (en) 2013-04-19 2018-06-26 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device
US20160022644A1 (en) * 2014-07-22 2016-01-28 Tsu-I Catherine Wang Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4602025A (en) * 1984-06-18 1986-07-22 Eli Lilly And Company Aromatase inhibitors
US4845227A (en) * 1984-06-18 1989-07-04 Eli Lilly And Company Aromatase inhibitors from azoles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
GB8726505D0 (en) * 1987-11-12 1987-12-16 Ici Plc Naphtho(2 1-b)furan derivatives
DE4330237C2 (de) 1993-09-02 1995-11-30 Schering Ag 1-Methylsubstituierte Androsta-1,4-dien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
AU2407997A (en) * 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
WO2002083241A1 (en) 2002-10-24
MXPA03009447A (es) 2004-05-24
NO20034246L (no) 2003-12-15
DE60229047D1 (de) 2008-11-06
HUP0304003A2 (hu) 2004-04-28
US20040171660A1 (en) 2004-09-02
SI1383578T1 (sl) 2008-12-31
ES2311599T3 (es) 2009-02-16
CN1551789A (zh) 2004-12-01
IL158396A0 (en) 2004-05-12
DK1383578T3 (da) 2008-11-03
SK14242003A3 (sk) 2004-03-02
BG108323A (bg) 2004-12-30
NO20034246D0 (no) 2003-09-23
CA2444980C (en) 2010-08-17
US8008333B2 (en) 2011-08-30
PL366744A1 (en) 2005-02-07
ATE409066T1 (de) 2008-10-15
EA011310B1 (ru) 2009-02-27
JP2004529924A (ja) 2004-09-30
BR0208920A (pt) 2004-04-20
YU81203A (sh) 2006-05-25
KR20040025916A (ko) 2004-03-26
NZ552873A (en) 2008-05-30
HRP20030839A2 (en) 2005-08-31
EP1383578A1 (en) 2004-01-28
EP1383578B1 (en) 2008-09-24
PT1383578E (pt) 2008-10-08
CZ20033107A3 (en) 2004-03-17
UA82648C2 (uk) 2008-05-12
EA200301128A1 (ru) 2004-04-29
AU2002249043B2 (en) 2008-01-10
ZA200307516B (en) 2004-09-27
CA2444980A1 (en) 2002-10-24
AR034036A1 (es) 2004-01-21
CY1108648T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EE200300497A (et) Pürasoolderivaadid HIV raviks
PT1485127E (pt) Administração de agentes para o tratamento de inflamação
DE60310415D1 (de) Therapeutische aerosolvorrichtung
DE60202452D1 (de) Pyridazinonaldose reductase inhibitoren
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
DE60208982D1 (de) Fussbad
NO20033205D0 (no) Terapeutiske kromanforbindelser
DE50209245D1 (de) Neuroprotektives medikament
DE60220060D1 (de) Wirbelbildung inhibitor mit opferkörper
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
DK1553950T3 (da) Terapeutisk behandling
DE60222664D1 (de) Hautbehandlungsmittel
NO20050689L (no) Terapeutisk anvendelse
DE60326190D1 (de) des Körpers
DE10197149T1 (de) Anti-Zusetz-Behandlungen
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
NO20034246L (no) Enkel dose av aromataseinhibitor for behandling av ufruktbarhet
IL162492A0 (en) Use of alkylphosphocholines for the preventative treatment of protozoandiseases
DE10157913B4 (de) Therapietisch
SE0103854D0 (sv) Therapeutic agents
SE0103855D0 (sv) Therapeutic agents
SE0200450D0 (sv) Therapeutic agents

Legal Events

Date Code Title Description
HE1A Change of address